Baseline characteristics
| Ablation patients (n=16) | |
|---|---|
| Age, years | 70±15 |
| Women, n (%) | 12 (75) |
| Body mass index, kg/m2 | 23±4 |
| NYHA class III/IV, n (%) | 12 (75) |
| Syncope, n (%) | 5 (31) |
| Atrial fibrillation, n (%) | 2 (13) |
| Previous stroke, n (%) | 2 (13) |
| Hypertension, n (%) | 8 (50) |
| Diabetes mellitus, n (%) | 2 (13) |
| Dyslipidaemia, n (%) | 8 (50) |
| Current smoker, n (%) | 2 (13) |
| Chronic obstructive pulmonary disease, n (%) | 0 (0) |
| Coronary artery disease, n (%) | 1 (6) |
| Previous myectomy, n (%) | 0 (0) |
| Previous septal ablation, n (%) | 1 (6) |
| Family history of HCM, n (%) | 2 (13) |
| Intraventricular septum thickness, mm | 15±2 |
| End-diastolic diameter, mm | 42±5 |
| End-systolic diameter, mm | 23±3 |
| Resting LVOT gradient, mm Hg | 107±45 |
| LVEF, % | 78±6 |
| ICD, n (%) | 5 (31) |
| Permanent pacemaker, n (%) | 0 (0) |
| β-blocker, n (%) | 16 (100) |
| Calcium-channel blocker, n (%) | 6 (38) |
| Na channel antagonist, n (%) | 8 (50) |
| Amiodarone, n (%) | 1 (6) |
| Diuretics, n (%) | 3 (19) |
| Warfarin, n (%) | 3 (19) |
Data are expressed as mean±SD or n (%).
HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; NYHA, New York Heart Association.